Bellerophon to Present at the Jefferies Virtual Healthcare Conference
Bellerophon Therapeutics (Nasdaq: BLPH) announces CEO Fabian Tenenbaum will present a corporate overview at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. The presentation is scheduled for June 3, 2021, at 3:00 PM Eastern Time. Bellerophon focuses on innovative treatments for cardiopulmonary diseases, currently developing multiple candidates under its proprietary INOpulse® program. A live audio webcast and replay will be available on the Company’s website, providing investors with real-time access to this key event.
- None.
- None.
WARREN, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the Jefferies Virtual Healthcare Conference, being held June 1-4, 2021.
Presentation Details
| Date: | Thursday, June 3, 2021 |
| Time: | 3:00 PM Eastern Time |
A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s website at www.bellerophon.com.
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.
Contacts
LifeSci Advisors:
Brian Ritchie
(212) 915-2578
britchie@lifesciadvisors.com
FAQ
When will Bellerophon Therapeutics present at the Jefferies Virtual Healthcare Conference?
Who is presenting for Bellerophon Therapeutics at the Jefferies Conference?
What is the focus of Bellerophon Therapeutics?
Where can I access the presentation by Bellerophon Therapeutics?
What is the stock symbol for Bellerophon Therapeutics?
